Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3026 in advanced solid tumors
NCT07327632Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI3026 in solid tumor, sponsored by Innovent Biologics. Primary endpoints: Adverse Event at 2 years, Serious Adverse Event at 2 years and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
IBI3026
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07327632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327632.